PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth 50-75% of AXSM's 17.05%. Bruce Berkowitz would examine spending effectiveness.
23.98%
G&A growth above 1.5x AXSM's 12.72%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses change of 7.46% while AXSM maintains costs. Bruce Berkowitz would investigate efficiency.
15.26%
Similar operating expenses growth to AXSM's 16.05%. Walter Schloss would investigate norms.
15.26%
Similar total costs growth to AXSM's 16.05%. Walter Schloss would investigate norms.
-36.68%
Both companies reducing interest expense. Martin Whitman would check industry trends.
7.46%
D&A growth less than half of AXSM's 42.19%. David Dodd would verify if efficiency is sustainable.
-50.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-43.14%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.01%
Share count change of 5.01% while AXSM is stable. Bruce Berkowitz would verify approach.
5.01%
Diluted share change of 5.01% while AXSM is stable. Bruce Berkowitz would verify approach.